 Neoplasm, Residual
"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 3 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 3 | 5 | | 2013 | 1 | 2 | 3 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 2 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 2 | 3 | 5 | | 2018 | 2 | 3 | 5 | | 2019 | 3 | 6 | 9 | | 2020 | 3 | 4 | 7 | | 2021 | 0 | 8 | 8 | | 2022 | 0 | 9 | 9 | | 2023 | 0 | 4 | 4 | | 2024 | 5 | 5 | 10 | | 2025 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Nachmias B, Haran A, Yisraeli Salman M, Stein EM. Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights. Br J Haematol. 2025 Oct; 207(4):1192-1212.
-
Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, Yoshino T, Heath EI, Lou E, Liu SV, Marshall JL, El-Deiry WS, Shields AF, Dietrich MF, Nakamura Y, Fujisawa T, Demetri GD, Barker A, Xiu J, Sacchetti DA, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert DD, Oberley M, Radovich M, Sledge GW, Spetzler DB. Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. Sci Rep. 2025 Jul 01; 15(1):21173.
-
Mumme HL, Huang C, Ohlstrom D, Bakhtiari M, Raikar SS, DeRyckere D, Qayed M, Castellino SM, Wechsler DS, Porter CC, Graham DK, Bhasin SS, Bhasin M. Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas. Nat Commun. 2025 May 02; 16(1):4114.
-
Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F, González Y, Teruel AI, Pardo JL, López de la Guía A, Sampol A, Ríos-Tamayo R, Sureda A, Gutiérrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J, Rosiñol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
-
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
Williams H, Omer DM, Thompson HM, Lin ST, Verheij FS, Miranda J, Yuval JB, Buckley J, Marco MR, Qin LX, Dombroski DA, Kedar R, Oto A, Korngold E, Veniero JC, Gandhi S, Krishnaraj A, Jagtiani M, Ohanian K, Vu D, Hope TA, Lee S, Wasnik AP, Madhuripan N, Gollub MJ, Garcia-Aguilar J. MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.
-
Schwartz MS, Muffly LS. Predicting relapse in acute lymphoblastic leukemia. Leuk Lymphoma. 2024 Dec; 65(13):1934-1940.
-
Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, Abdulhaq H, Mateos MV, Laubach J, Weisel K, Ludwig H, Rajkumar SV, Sonneveld P, Jackson G, Morgan G, Richardson PG. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024 08 12; 14(1):134.
-
Thor A, Myklebust MP, Grenabo Bergdahl A, Lundgren PO, Skokic V, Almås B, Haugnes HS, Tandstad T, Akre O, Cohn-Cedermark G, Dahl O, Kjellman A. miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. J Urol. 2024 Nov; 212(5):720-730.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|